Clinical trial
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus…
NCT00044447 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00044447 |
|---|---|
| Title | Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione |
| Official title | A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Non-Insulin-Dependent |
| Intervention type | Drug |
| Interventions | Glimepiride |
| Enrollment | 170 |
| Start date | May 1, 2001 |
| Completion | Sep 1, 2002 |
| First posted | Aug 30, 2002 |
| Last update posted | Jun 19, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: